Hyderabad: Sales of weight-loss drugs Wegovy by Danish pharmaceutical giant Novo Nordisk and Mounjaro by U.S.-based Eli Lilly ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

A man who says he got 'Ozempic penis' from the weight loss drug Wegovy has opened up on how his sex life has been going ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

A trial of 3,127 patients who took a daily pill for 72 weeks saw an average weight loss per person of 12.3kg. While ...

Lilly executives have touted the once-daily pill, known as orforglipron, as a cheaper alternative to recently-popular obesity injections like its Zepbound offering or Novo’s Wegovy. Both of the ...

In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...